The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 15.66 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.66 — no flag raisedOK
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as VERACYTE, INC. reports it. History and quarterly detail are in the app.
- Testing revenue$493.2M
- Product revenue$14.3M
- Biopharmaceutical and other revenue$9.7M
- Biopharmaceutical revenue$6.5M
- Other Testing Revenue$6.2M
Leadership changes
From VERACYTE, INC.'s own filings, the day they're filed.
- Tom Miller · directors · appointment
Latest filings
- 10-Q · Quarterly report2026-07-31
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-06-11
- 10-Q · Quarterly report2026-05-06
- 8-K · Company announcement2026-05-05
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about VERACYTE, INC., every answer cited to the official filings🔒
- The Intelligence Brief — added when VERACYTE, INC.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.